Tech Center 1600 • Art Units: 1648 1671
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18046862 | MULTI-EPITOPE PAN-CORONAVIRUS VACCINE COMPOSITIONS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18046875 | LARGE SEQUENCE PAN-CORONAVIRUS VACCINE COMPOSITIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18046462 | PAN-CORONAVIRUS VACCINE COMPOSITIONS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17312916 | HIV SEROSIGNATURES FOR CROSS-SECTIONAL INCIDENCE ESTIMATION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 17433407 | NOVEL FISH CORONAVIRUS | Non-Final OA | Pharmaq AS |
| 17927548 | Adenovirus-Based SARS-CoV-2 Vaccine | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17393742 | COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | Non-Final OA | Roche Molecular Systems, Inc. |
| 17995850 | COMPOSITIONS, KITS, AND METHODS FOR ANTI-MICROBIAL SEROLOGY ASSAYS USING ANTI-HUMAN IMMUNOGLOBULIN ANTIBODY | Final Rejection | Siemens Healthcare Diagnostics Inc. |
| 18032920 | Cell-Free Method For The Quantitative Measurement Of Virus Neutralizing Antibodies | Non-Final OA | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) |
| 18017726 | IMPROVED AAV-MEDIATED X-LINKED RETINOSCHISIS THERAPIES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 17771625 | COMPOSITIONS AND METHODS FOR PRODUCING A VIRAL VACCINE WITH REDUCED PARTICLE SIZE | Final Rejection | Seqirus UK Limited |
| 17433732 | METHODS FOR PREVENTING DISEASE OR DISORDER CAUSED BY RSV INFECTION | Non-Final OA | Novavax, Inc. |
| 18263462 | CHIMERIC ADENOVIRAL VECTORS | Non-Final OA | Vaxart, Inc. |
| 17481781 | CORONAVIRUS VACCINES AND METHODS OF USE | Final Rejection | BioNTech US Inc. |
| 18314769 | COMPOSITION AND METHOD TO STABILIZE CORONAVIRUS SPIKE GLYCOPROTEINS IN PRE-FUSION CONFORMATION | Non-Final OA | The Research Foundation for The State of University New York |
| 18182030 | PROTEASE BIOSENSORS AND METHODS OF VIRUS DETECTION | Non-Final OA | Montana Molecular LLC |
| 18017175 | INSULIN RECEPTOR-MEDIATED ENHANCEMENT OF GENE TRANSFER | Non-Final OA | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 17999487 | METHOD FOR INACTIVATING SARS-COV-2 AND ITS USE FOR DETECTING ANTIBODIES | Non-Final OA | DIESSE DIAGNOSTICA SENESE S.P.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy